ICU vs RNAZ

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 14, 2026

ICU

53.7
AI Score
VS
ICU Wins

RNAZ

48.9
AI Score

Investment Advisor Scores

ICU

54score
Recommendation
HOLD

RNAZ

49score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ICU RNAZ Winner
Net Income -12.15M -17.79M ICU
Operating Income -12.18M -17.76M ICU
ROE -116.6% -1421.2% ICU
ROA -85.8% -11.3% RNAZ
Total Assets 14.16M 157.16M RNAZ
Cash 11.98M 12.84M RNAZ
Current Ratio 3.63 3.11 ICU

Relative Price Performance (Last 90 Days)

ICU 1M: -14.4% · 3M: -14.4% RNAZ 1M: -52.2% · 3M: -53.6%

Current Technical Phase

ICU

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.3%), weak momentum, RSI 42

RSI (14): 42.2 · Price: $3.21

RNAZ

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.0%), weak momentum, RSI 27

RSI (14): 26.9 · Price: $2.84

Fundamentals Snapshot

Metric ICU RNAZ
Market Cap
Forward P/E -1.4 -9.0
Trailing P/E
Revenue (TTM)
Revenue Growth 0.8% 0.0%
Gross Margin 0.9%
Operating Margin -6.2% 0.0%
EPS -1.92 -41.82
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ICU is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.